Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
454.89B
Market cap454.89B
Price-Earnings ratio
20.12
Price-Earnings ratio20.12
Dividend yield
2.70%
Dividend yield2.70%
Average volume
8.78M
Average volume8.78M
High today
High today
Low today
Low today
Open price
$184.89
Open price$184.89
Volume
0.00
Volume0.00
52 Week high
$189.92
52 Week high$189.92
52 Week low
$140.68
52 Week low$140.68

JNJ News

The Motley Fool 11h
Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio

These two market leaders have increased their dividends for a combined 115 years. It's impossible to predict with certainty whether a recession is coming, but...

Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio
Nasdaq 15h
Johnson & Johnson Hit With $966 Mln Verdict In Talc Lawsuit

(RTTNews) - Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $966 million to the family of a California woman who died from a rare and aggressiv...

Johnson & Johnson Hit With $966 Mln Verdict In Talc Lawsuit
TipRanks 17h
Protagonist Therapeutics price target raised to $74 from $62 at Clear Street

Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $74 from $62 and keeps a Buy rating on the shares. The price target hike follo...

Analyst ratings

52%

of 25 ratings
Buy
52%
Hold
44%
Sell
4%

More JNJ News

Bloomberg 17h
J&J Must Pay Record $966 Million in Talc Baby Powder Cancer Case

Johnson & Johnson was told by a California jury to pay $966 million to the family of a deceased woman who blamed her cancer on life-long use of the company’s ba...

J&J Must Pay Record $966 Million in Talc Baby Powder Cancer Case
Simply Wall St 18h
How Will U.S. Orthopaedic Partners Deal Shape Johnson & Johnson’s Medtech Growth Strategy?

In the past week, U.S. Orthopaedic Partners announced a new agreement selecting Johnson & Johnson as its official vendor for total joint products, giving the ph...

How Will U.S. Orthopaedic Partners Deal Shape Johnson & Johnson’s Medtech Growth Strategy?
TipRanks 21h
Jury awards $966M in talc verdict against Johnson & Johnson, Law.com reports

A jury in Los Angeles Superior Court awarded a $966M verdict against Johnson & Johnson to the children of a woman who died of mesothelioma in what was the highe...

Nasdaq 23h
JNJ Quantitative Stock Analysis

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...

JNJ Quantitative Stock Analysis
Nasdaq 23h
Johnson & Johnson Reports Positive Phase 2b Results For Icotrokinra In Ulcerative Colitis

(RTTNews) - Johnson & Johnson (JNJ) on Tuesday announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra in adults with moderately t...

Johnson & Johnson Reports Positive Phase 2b Results For Icotrokinra In Ulcerative Colitis
TipRanks 24h
Johnson & Johnson’s Acuvue contact lens shows efficacy in studies

Johnson & Johnson announced new data on the Acuvue Oasys Max 1-Day for Astigmatism contact lenses which showed higher end-of-day comfort as compared to Dailies...

TipRanks 24h
Johnson & Johnson announces 48-week data from Phase 3 ASTRO study

Johnson & Johnson announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA subcutaneous induction and maintenance therapy in adults with moder...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.